Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
